Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease
Objective: We present a wearable inertial system for the evaluation of motor symptoms in Parkinson's Disease. Background: PD is the second neurodegenerative disease affecting to around…Validation of the Hebrew version of the Unified Dyskinesia Rating Scale (UDysRS)
Objective: To assess the clinimetric properties of the Hebrew version of the UDysRS. Background: Dyskinesia is a common side effect of dopaminergic treatments for Parkinson's…Preserved white matter microstructure in Parkinson’s disease patients with levodopa-induced dyskinesia: Evaluation by neurite orientation dispersion and density imaging (NODDI)
Objective: Brain microstructure alteration using MRI in Parkinson's disease (PD) have not been well studied. We analysis the white matter alterations in Parkinson’s disease with…Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection
Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…Cholecalciferol (VD3) attenuated motor deficits and dyskinesia in Hemi-Parkinsonian mice: behavioural, biochemical & electrophysiological implications
Objective: The study investigated the impacts of VD3 on behavioural indices, dopamine metabolism, DA transport, BDNF, corticostriatal neural activities and the possible mechanism of action…Blood–brain barrier breakdown in an adult mouse model of Parkinson’s disease
Objective: This study aims to evaluate the integrity of the blood-brain barrier (BBB) in parkinsonism. Background: Parkinson's disease (PD) is a neurodegenerative disorder which is…Spectrum of motor complications in advanced Parkinson’s disease: data from a large Romanian case series evaluated for suitability for device aided therapy
Objective: The objective was to describe the spectrum of motor complications in a large cohort of patients with advanced Parkinson’s Disease (APD) who received at…Contribution of pedunculopontine nucleus cholinergic neurons to L-DOPA-induced dyskinesia and PD motor deficits in hemi-parkinsonian rats
Objective: To determine if chemogenetic and pharmacological modulation of pedunculopontine nucleus (PPN) cholinergic neurons can alter L-DOPA-induced dyskinesia and gait deficits in hemi-parkinsonian rats. Background:…Cortical gamma oscillations as biomarkers for levodopa-induced dyskinesia
Objective: The aim of our study was to characterize cortical neuronal network activity in levodopa-induced dyskinesia in order to better understand the underlying pathophysiology and…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 49
- Next Page »